Shizuo Yamada

Prof. Dr. Shizuo Yamada

University of Shizuoka, Shizuoka, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Shizuo YamadaShizuo Yamada
Shizuo Yamada
YIYoshihiko Ito
Yoshihiko Ito
SNSaori Nishijima
Saori Nishijima
KKKatsumi Kadekawa
Katsumi Kadekawa
KSKimio Sugaya
Kimio Sugaya

1 September 2011 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
SOSatomi Onoue
Satomi Onoue
AUAtsushi Uchida
Atsushi Uchida
HTHaruki Takahashi
Haruki Takahashi
YSYoshiki Seto
Yoshiki Seto
YKYohei Kawabata
Yohei Kawabata
Shizuo YamadaShizuo Yamada
Shizuo Yamada

5 March 2009 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
MSMayumi Suzuki
Mayumi Suzuki
YIYoshihiko Ito
Yoshihiko Ito
TFTomomi Fujino
Tomomi Fujino
MAMasayuki Abe
Masayuki Abe
KUKeizo Umegaki
Keizo Umegaki
Shizuo YamadaShizuo Yamada
Shizuo Yamada
Saw palmetto extract (SPE), an extract from the ripe berries of the American dwarf palm, has been widely used as a therapeutic remedy for urinary dysfunction due to benign prostatic hyperplasia (BPH) in Europe. Numerous mechanisms of action have been proposed for SPE, including the inhibition of 5α-reductase. Today, α1-adrenoceptor antagonists and muscarinic cholinoceptor antagonists are commonly used in the treatment of men with voiding symptoms secondary to BPH. The improvement of voiding symptoms in patients taking SPE may arise from its binding to pharmacologically relevant receptors in the lower urinary tract, such as α1-adrenoceptors, muscarinic cholinoceptors, 1,4-dihyropyridine receptors and vanilloid receptors. Furthermore, oral administration of SPE has been shown to attenuate the up-regulation of α1-adrenoceptors in the rat prostate induced by testosterone. Thus, SPE at clinically relevant doses may exert a direct effect on the pharmacological receptors in the lower urinary tract, thereby improving urinary dysfunction in patients with BPH and an overactive bladder. SPE does not have interactions with co-administered drugs or serious adverse events in blood biochemical parameters, suggestive of its relative safety, even with long-term intake. Clinical trials (placebo-controlled and active-controlled trials) of SPE conducted in men with BPH were also reviewed. This review should contribute to the understanding of the pharmacological effects of SPE in the treatment of patients with BPH and associated lower urinary tract symptoms (LUTS).

31 March 2009 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
YIYoshihiko Ito
Yoshihiko Ito
LOLuvsandorj Oyunzul
Luvsandorj Oyunzul
MSMasanao Seki
Masanao Seki
T(Tomomi Fujino (Oki)
Tomomi Fujino (Oki)
MMMinoru Matsui
Minoru Matsui
Shizuo YamadaShizuo Yamada
Shizuo Yamada

1 February 2011 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
Shizuo YamadaShizuo Yamada
Shizuo Yamada
MSMasanao Seki
Masanao Seki
MOMasaki Ogoda
Masaki Ogoda
AFAyako Fukata
Ayako Fukata
MNMiho Nakamura
Miho Nakamura
YIYoshihiko Ito
Yoshihiko Ito
The binding of orally administered imidafenacin, used to treat overactive bladders, to muscarinic receptors in rat tissue was characterized based on pharmacokinetics. The binding in six tissues including bladder tissue was measured using [N-methyl-3H] scopolamine methyl chloride ([3H]NMS). Pharmacokinetic parameters were estimated from measurements of the concentration of imidafenacin in serum, the bladder, and the submaxillary gland by liquid chromatography-mass spectrometry/mass spectrometry. The receptor binding affinity of imidafenacin in vitro was significantly lower in the bladder than submaxillary gland or colon. The oral administration of imidafenacin (0.79, 1.57, and 6.26 μmol/kg) was characterized by a more selective and longer-lasting binding to muscarinic receptors in the bladder than other tissues. Imidafenacin showed little binding to brain muscarinic receptors, consistent with its minor effect on the central nervous system. Pharmacokinetic data showed that orally administered imidafenacin was distributed at a higher concentration in the bladder than the serum or submaxillary gland of rats. After the intravesical instillation of imidafenacin, there was significant binding of muscarinic receptors in the bladder. Furthermore, a significant level of imidafenacin was detected in the urine of rats given a 1.57 μmol/kg concentration of this agent. The present study demonstrated that imidafenacin administered orally distributes predominantly to the bladder and exerts more selective and longer-lasting effect on the bladder than other tissues, such as the submaxillary gland, colon, and brain. Furthermore, the imidafenacin excreted in urine may play an important role in pharmacokinetic and pharmacological selectivity.

1 June 2008 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
SMShuji Maruyama
Shuji Maruyama
HTHideo Tsukada
Hideo Tsukada
SNShingo Nishiyama
Shingo Nishiyama
TKTakeharu Kakiuchi
Takeharu Kakiuchi
DFDai Fukumoto
Dai Fukumoto
Shizuo YamadaShizuo Yamada
Shizuo Yamada
We evaluated the effects of five clinically used antimuscarinic agents for overactive bladder (OAB) treatment on in vivo muscarinic receptor binding in rat brain by quantitative autoradiography. There was a dose-related decrease in in vivo specific (+)N-[11C]methyl-3-piperidyl benzilate ([11C](+)3-MPB) binding in each brain region of rats 10 min after i.v. injection of oxybutynin, propiverine, solifenacin, and tolterodine. Rank order of the i.v. dose for 50% receptor occupancy (RO50) of antimuscarinic agents in rat brain regions was propiverine > solifenacin > tolterodine, oxybutynin. There was a good linear relationship between in vivo (pRO50 values in the rat hippocampus) and in vitro (pKi values in human M1 receptors) receptor binding activities of propiverine, solifenacin, and tolterodine. The observed RO50 value of oxybutynin was approximately five times smaller than the predicted in vitro Ki value. The dose ratios of antimuscarinic agents for the brain receptor occupancy (RO50) to the inhibition of carbachol- and volume-induced increases in intravesical pressure (ID50), which reflects in vivo selectivity for the urinary bladder over the brain, were greater for solifenacin, tolterodine, and propiverine than oxybutynin. Darifenacin displayed only a slight decrease in specific [11C](+)3-MPB binding in the rat brain regions, and it was not dose-related. In conclusion, in vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy may provide fundamental basis for managing central nervous system (CNS) side effects in antimuscarinic therapy for OAB. It is suggested that in the treatment of OAB, CNS side effects can be avoided by antimuscarinic agents with high selectivity for the urinary bladder over the brain.